Advertisement

Loading...

Wuhan YZY Biopharma Co Ltd

2496.HKHKSE
Healthcare
Biotechnology
HK$4.13
HK$0.08(1.98%)
Hong Kong Market is Open • 10:08

Wuhan YZY Biopharma Co Ltd (2496.HK) Stock Competitors & Peer Comparison

See (2496.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2496.HKHK$4.13+1.98%800.9M-8.98-HK$0.46N/A
6160.HKHK$185.60+8.47%257.8B115.17HK$1.49N/A
1801.HKHK$91.00+5.69%146.1B160.19HK$0.53N/A
2269.HKHK$35.10+11.93%136.5B25.21HK$1.31N/A
9926.HKHK$139.50+4.81%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.37+8.89%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.32+4.28%53.4B20.77HK$1.09+1.10%
9995.HKHK$111.20+12.49%52.7B65.62HK$1.46N/A
3759.HKHK$20.80+13.85%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.15+7.90%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2496.HK vs 6160.HK Comparison April 2026

2496.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2496.HK stands at 800.9M. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 2496.HK is priced at HK$4.13, while 6160.HK trades at HK$185.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2496.HK currently has a P/E ratio of -8.98, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 2496.HK's ROE is +8.43%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 2496.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2496.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions